We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-4.22%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$740M
AUM Growth
+$30.5M
Cap. Flow
-$240M
Cap. Flow %
-32.47%
Top 10 Hldgs %
67%
Holding
218
New
54
Increased
59
Reduced
50
Closed
36

Top Buys

Rank Stock Value
1
BTBT icon
Bit Digital
BTBT
+$40.7M
2
SLAI
SOLAI Ltd ADS
SLAI
+$15.2M
3
VRPX
Virpax Pharmaceuticals, Inc. Common Stock
VRPX
+$7.02M
4
FLUX icon
Flux Power
FLUX
+$6.05M
5
VXX icon
iPath Series B S&P 500 VIX Short-Term Futures ETN
VXX
+$5.87M

Top Sells

Rank Stock Value
1
LNAI
Lunai Bioworks
LNAI
+$7.71M
2
ATOS icon
Atossa Therapeutics
ATOS
+$4.06M
3
ATER icon
Aterian
ATER
+$4M
4
ASXC
Asensus Surgical, Inc.
ASXC
+$2.95M
5
RDHL
Redhill Biopharma
RDHL
+$2.34M

Sector Composition

Rank Sector Weight
1 Miscellaneous 77.12%
2 Healthcare 8.81%
3 Financials 5.55%
4 Technology 3.48%
5 Industrials 1.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GYRE icon
126
CALL
Gyre Therapeutics
GYRE
$689M
$350K 0.05%
+114
New +$3.75K
PRFX icon
127
PRF Technologies Ltd
PRFX
$3.02M
$326K 0.04%
98
-192
-66% -$670K
SBEV.WS
128
DELISTED
Splash Beverage Group, Inc. Warrants to purchase 1/40th of a share of Common Stock at an exercise price of $184.00
SBEV.WS
$321K 0.04%
605,659
-254,950
-30% -$231K
RCON icon
129
PUT
Recon Technology
RCON
$553K
– –
0
– –
VEEE icon
130
Twin Vee PowerCats
VEEE
$5.36M
$319K 0.04%
+240
New +$392K
NCTY
131
CALL
The9 Ltd
NCTY
$58.2M
$297K 0.04%
29
-13
-31% -$1.64K
DMK
132
PUT
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
$293K 0.04%
+43
New +$3.15K
PHIO icon
133
PUT
Phio Pharmaceuticals
PHIO
$12M
$281K 0.04%
13
-2
-13% -$418
QTEX
134
QTREX Quantum
QTEX
$57.7M
$275K 0.04%
+102,553
New +$377K
AUTL
135
CALL
Autolus Therapeutics
AUTL
$503M
$268K 0.04%
+409
New +$2.58K
UK icon
136
Ucommune International Ltd Class A Ordinary Shares
UK
$1.34M
$260K 0.04%
124
+82
+195% +$258K
INFI
137
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$241K 0.03%
70,431
-371,042
-84% -$1.14M
ATNM icon
138
Actinium Pharmaceuticals
ATNM
$39.3M
$235K 0.03%
+26,488
New +$184K
ADOM
139
DELISTED
ADOMANI Inc
ADOM
$232K 0.03%
850,000
-5,316,711
-86% -$1.45M
TRIL
140
CALL
DELISTED
Trillium Therapeutics Inc.
TRIL
$211K 0.03%
120
-1
-0.8% -$12
DMK
141
CALL
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
$210K 0.03%
+31
New +$2.27K
ADTX
142
DELISTED
ADITXT INC
ADTX
– –
0
– –
QTEXW
143
DELISTED
QTREX Quantum Warrant
QTEXW
$208K 0.03%
+253,063
New +$249K
HMCOW
144
DELISTED
HumanCo Acquisition Corp. Warrant
HMCOW
$198K 0.03%
200,314
– –
PLUR icon
145
PUT
Pluri
PLUR
$14.1M
$197K 0.03%
93
+27
+41% +$691
SRGA
146
PUT
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$193K 0.03%
+59
New +$2.16K
ATNM icon
147
CALL
Actinium Pharmaceuticals
ATNM
$39.3M
$182K 0.02%
+205
New +$1.43K
ABVC icon
148
ABVC BioPharma
ABVC
$27.7M
$165K 0.02%
+7,156
New +$203K
NOVN
149
DELISTED
Novan, Inc. Common Stock
NOVN
$156K 0.02%
19,132
– –
ATHX
150
DELISTED
Athersys, Inc. Common Stock
ATHX
$155K 0.02%
4,658
-9,158
-66% -$348K
4 5
6
7 8

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q3 2021 Portfolio in Review

As of Q3 2021, Sabby Management held 218 positions worth $740M, up 4.3% from $709M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Sabby Management withdrew a net $240M in Q3 2021, closing 36 positions and reducing 50 holdings. Its most notable exit was Atossa Therapeutics, an estimated $4.06M position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 77% of assets, down from 81% a quarter earlier, followed by Healthcare and Financials.

Against the trend, Sabby Management opened a new position in Bit Digital worth $30.5M.

  • Sabby Management's largest Q3 2021 buy was Bit Digital: 4,216,310 shares worth $30.5M.
  • Sabby Management added most to Virpax Pharmaceuticals, Inc. Common Stock in Q3 2021, an estimated $7.02M increase.
  • Sabby Management's biggest Q3 2021 reduction was Lunai Bioworks, cutting an estimated $7.71M.
  • Sabby Management fully exited Atossa Therapeutics in Q3 2021, selling an estimated $4.06M.
  • Sabby Management's ten largest holdings make up 67% of its $740M portfolio in Q3 2021.
  • Sabby Management opened 54 new positions and closed 36 in Q3 2021.
  • Sabby Management's portfolio value rose 4.3% quarter-over-quarter to $740M.

Based on Sabby Management's 13F filing for Q3 2021, filed 15 Nov 2021.